J. Anim Sci.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ji, S. Q.
Right arrow Articles by Spurlock, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ji, S. Q.
Right arrow Articles by Spurlock, M. E.

Journal of Animal Science, Vol 76, Issue 5 1389-1395, Copyright © 1998 by American Society of Animal Science

CLINICAL TRIAL

Porcine somatotropin improves growth in finishing pigs without altering calpain 3 (p94) or alpha-actin mRNA abundance and has a differential effect on calpastatin transcription products

S. Q. Ji, G. R. Frank, S. G. Cornelius, G. M. Willis and M. E. Spurlock
Swine Research Group, Purina Mills, Inc., St. Louis, MO 63144, USA.

The objective of this study was to determine whether the improvements in growth and efficiency of gain achieved by recombinant porcine somatotropin (pST) are associated with altered expression of the p94, calpastatin, or alpha-actin genes in porcine longissimus (LD) muscle. Forty-eight barrows (initial 64.2 to 67.4 kg BW) were assigned to four treatments (n = 12) arranged as a 2 x 2 factorial in a randomized complete block design. Factors were duration of treatment (3 or 6 wk) and pST administration (0 or 3 mg x pig(-1) x d(-1)). Plasma samples were obtained 24 h after the first pST injection and at the end of the each treatment period for assays of selected variables. The LD samples were obtained at 3 and 6 wk of pST treatment. Northern blot analysis of calpastatin expression in LD muscle revealed three distinct transcription products of approximately 8.5 (CPST I), 5.5 (CPST II), and 2.5 (CPST III) kb; CPST II was reduced (P < .02) 33 and 61% by pST at 3 and 6 wk, respectively, whereas CPST I and III were not influenced (P > .12). Neither alpha-actin nor p94 was responsive to pST injection. As expected, pST resulted in higher (50%, P < .02) plasma insulin within 24 h and one- and twofold higher (P < .01) concentrations at 3 and 6 wk, respectively. Glucose was increased (P < .01) at 3 (15%) and 6 (10%) wk, whereas urea nitrogen was reduced (32 to 36%, P < .01). The efficacy of pST was evident in that ADG was improved (P < .01) 11 to 13% independent of time. Likewise, feed intake was reduced (P < .01) 10 to 11% and gain: feed improved (P < .01) approximately 26% for pigs receiving pST independent of time. These data indicate that the enhanced muscle growth achieved by pST is not associated with altered expression of p94 or alpha-actin, or an increase in the abundance of any calpastatin transcription product.


This article has been cited by other articles:


Home page
 J ANIM SCIHome page
P. L. Sensky, K. K. Jewell, K. J. P. Ryan, T. Parr, R. G. Bardsley, and P. J. Buttery
Effect of anabolic agents on calpastatin promoters in porcine skeletal muscle and their responsiveness to cyclic adenosine monophosphate-and calcium-related stimuli
J Anim Sci, November 1, 2006; 84(11): 2973 - 2982.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Ji, R. L. Losinski, S. G. Cornelius, G. R. Frank, G. M. Willis, D. E. Gerrard, F. F. S. Depreux, and M. E. Spurlock
Myostatin expression in porcine tissues: tissue specificity and developmental and postnatal regulation
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R1265 - R1273.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Animal Science.